Page 17 - GALENIKA MEDICAL JOURNAL

Literatura 12. Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS,
Nogueira AR, et al. Spironolactone Versus Clonidine as a Fourth-Drug
Therapy for Resistant Hypertension: The ReHOT Randomized Study
1. Leung AA, Williams JVA, Tran KC, Padwal RS. Epidemiology of Resistant (Resistant Hypertension Optimal Treatment). Hypertens Dallas Tex
Hypertension in Canada. Can J Cardiol. 2022;38(5):681-7. 1979. 2018;71(4):681-90.
2. Egan BM, Cui MX. Characteristics of Adults With Apparent Treatment 13. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G,
Resistant Hypertension: Six Factors Impacting Prevalence-Editorial et al. Spironolactone versus placebo, bisoprolol, and doxazosin to
Commentary. Hypertens Dallas Tex 1979. 2023;80(9):1856-9. determine the optimal treatment for drug-resistant hypertension
(PATHWAY-2): a randomised, double-blind, crossover trial. Lancet Lond
3. Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun Engl. 2015;386(10008):2059-68.
DA, et al. Treatment-Resistant Hypertension and Outcomes Based on
Randomized Treatment Group in ALLHAT. Am J Med. 2017;130(4):439- 14. Secora AM, Shin JI, Qiao Y, Alexander GC, Chang AR, Inker LA, et al.
448.e9. Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among
Patients with Heart Failure. Mayo Clin Proc. 2020;95(11):2408-19.
4. Hwang AY, Dietrich E, Pepine CJ, Smith SM. Resistant Hypertension:
Mechanisms and Treatment. Curr Hypertens Rep. 2017;19(7):56. 15. Trujillo H, Caravaca-Fontán F, Caro J, Morales E, Praga M. The Forgotten
Antiproteinuric Properties of Diuretics. Am J Nephrol. 2021;52(6):435-49.
5. Bourque G, Hiremath S. Rethinking Resistant Hypertension. J Clin Med.
2022;11(5):1455. 16. Kim KY. Association between health-related quality of life and
nonadherence to antihypertensive medication. Nurs Open.
6. Fadl Elmula FEM, Hoffmann P, Larstorp AC, Fossum E, Brekke M, 2023;10(6):3570-8.
Kjeldsen SE, et al. Adjusted drug treatment is superior to renal
sympathetic denervation in patients with true treatment-resistant 17. Souza ACC de, Borges JWP, Moreira TMM. Quality of life and treatment
hypertension. Hypertens Dallas Tex 1979. 2014;63(5):991-9. adherence in hypertensive patients: systematic review with meta-
analysis. Rev Saude Publica. 2016;50:71.
7. Bakris G, Yang YF, Pitt B. Mineralocorticoid Receptor Antagonists for
Hypertension Management in Advanced Chronic Kidney Disease: 18. Oliveras A, de la Sierra A. Resistant hypertension: patient
BLOCK-CKD Trial. Hypertens Dallas Tex 1979. 2020;76(1):144-9. characteristics, risk factors, co-morbidities and outcomes. J Hum
Hypertens. 2014;28(4):213-7.
8. Janković SM, Stojković S, Petrović M, Kostić T, Zdravković M,
Radovanović S, et al. Results of the trycort: Cohort study of add-on
antihypertensives for treatment of resistant hypertension. Medicine
(Baltimore). 2023;102(22):e33941. Konflikt interesa: Nema
9. WMA - The World Medical Association-WMA Declaration of Helsinki Primljeno: 10. 11. 2024.
– Ethical Principles for Medical Research Involving Human Subjects Prihvaćeno: 21. 11. 2024.
[Internet]. [cited 2024 Aug 23]. Available online: https://www.wma.net/
policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical- Onlajn: 31. 12. 2024.
research-involving-human-subjects/.
10. Shalaeva EV, Messerli FH. What is resistant arterial hypertension? Blood
Press. 2023;32(1):2185457.
11. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison
Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/
ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation,
and Management of High Blood Pressure in Adults: Executive
Summary: A Report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines. Hypertens
Dallas Tex 1979. 2018;71(6):1269-324.

ORIGINALNI RADOVI Galenika Medical Journal, 2024; 3(12):7-15. 15